NASDAQ · AXGN
Healthcare · Medical - Devices
$48.30
Down-$0.78 (-1.61%)
Updated Sep 3, 2026, 3:36 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
AXGN closed at $48.30 after 21 trading sessions, up 6.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $50.15 | $51.50 | $47.83 | $48.30 | 789.92K |
| Sep 1, 2026 | $50.64 | $51.00 | $49.29 | $49.88 | 596.57K |
| Aug 31, 2026 | $50.97 | $51.18 | $49.63 | $50.76 | 878.14K |
| Aug 28, 2026 | $51.55 | $52.43 | $50.94 | $51.47 | 772.18K |
| Aug 27, 2026 | $51.88 | $52.91 | $51.16 | $51.73 | 951.57K |
| Aug 26, 2026 | $50.04 | $51.99 | $49.25 | $51.58 | 848.63K |
| Aug 25, 2026 | $49.68 | $50.00 | $48.7571 | $49.93 | 537.32K |
| Aug 24, 2026 | $50.88 | $50.88 | $48.74 | $49.23 | 704.12K |
| Aug 21, 2026 | $46.50 | $51.06 | $46.24 | $50.40 | 1.78M |
| Aug 20, 2026 | $48.45 | $49.18 | $45.255 | $46.44 | 1.03M |
| Aug 19, 2026 | $50.50 | $50.62 | $48.87 | $48.93 | 982.91K |
| Aug 18, 2026 | $49.40 | $50.66 | $48.795 | $50.19 | 975.19K |
| Aug 17, 2026 | $48.51 | $49.205 | $47.90 | $49.15 | 654.2K |
| Aug 14, 2026 | $48.16 | $48.805 | $47.29 | $48.73 | 632.31K |
| Aug 13, 2026 | $49.20 | $49.929 | $47.59 | $48.05 | 760.45K |
| Aug 12, 2026 | $48.50 | $49.90 | $48.26 | $49.67 | 716.48K |
| Aug 11, 2026 | $48.21 | $49.12 | $47.31 | $48.48 | 576.93K |
| Aug 10, 2026 | $46.03 | $48.72 | $45.95 | $48.22 | 978.34K |
| Aug 7, 2026 | $44.75 | $46.54 | $44.415 | $46.43 | 713K |
| Aug 6, 2026 | $45.07 | $45.615 | $44.11 | $44.35 | 550.94K |
| Aug 5, 2026 | $45.59 | $45.59 | $44.2501 | $45.22 | 968.88K |
The latest Smart Investors Daily articles mentioning AXGN.
AXGN research
Company profile and research snapshot.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 26, 2026 | Truist Securities | Buy | — |
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| Jul 30, 2026 | Citizens | Market Outperform | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 29, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 26, 2026
Truist Securities analyst Ravi Misra initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Target of $60.
Yahoo · Jul 15, 2026
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the con
SeekingAlpha · Mar 6, 2026
Axogen, Inc. (AXGN) 47th Annual Raymond James Institutional Investor Conference March 3, 2026 3:25 PM ESTCompany ParticipantsMichael Dale - President, CEO...
SeekingAlpha · Feb 25, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AXGN.
